Trial
NCT05335278
Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators
—
Condition
Interstitial Lung Disease
Intervention
Nintedanib 150 milligrams [Ofev]
Why stopped
Slow recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-02